-
Mashup Score: 0
Internationally recognized physician-scientist Lauren Averett Byers, M.D., Professor and Thoracic Section Chief of Thoracic/Head and Neck Medical Oncology at…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Lauren A. Byers Bio | American Association for Cancer Research - 3 month(s) ago
Lauren A. Byers Bio | American Association for Cancer Research h1#page-title { display: none; } #aacrcontent{margin: 0 20px; font-family: arial, elvetica, sans-serif; font-size: 16px;} #aacrcontent .aacrbio img{float: left; margin: 0 12px 12px 0; max-width: 216px; height: auto;} #aacrcontent .aacrbio a{font-weight: 700;} .bioQ{font-style: italic; font-weight: bold;} The Best of the AACR Journals Collection: Author Profiles Lauren A. Byers Title & Affiliation: Associate Professor and…
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
A few years ago I had the chance to thank Mrs. Kagi in an @AACR interview. “Ms. Alice Kagi…was passionate about biology. Her enthusiasm was contagious. She taught us that advances in molecular biology would transform diseases like cancer.” https://t.co/guGn4qoBQt https://t.co/HV05nufgaa
-
-
Mashup Score: 8Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes - 11 month(s) ago
Heeke et al. report robust assays utilizing gene expression and DNA methylation to distinguish small cell lung cancer subtypes from tissue and liquid biopsies. DNA methylation is distinct across SCLC subtypes and longitudinal assessment from liquid biopsies allows tracking of SCLC subtype evolution.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/UZWfZ22HEq
-
-
Mashup Score: 3Tina Cascone on NSCLC New Findings From the NeoCOAST Trial on Durvalumab-Based Therapy - The ASCO Post - 3 year(s) ago
AACR Annual Meeting 2022 Tina Cascone, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the findings of the phase II NeoCOAST study, which showed that combination immunotherapy with the anti–PD-L1 monoclonal antibody durvalumab and other novel agents resulted in numerically higher major pathologic response rates…
Source: ascopost.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ASCOPost: Tina Cascone, MD, PhD, on NSCLC: New Findings From the NeoCOAST Trial on Durvalumab-Based Therapy https://t.co/tPapYYit3c #AA…
-
-
Mashup Score: 2
Gay et al. provide a classification for four subtypes of small cell lung cancer, each with unique molecular features and therapeutic vulnerabilities. An inflamed, mesenchymal subtype predicts benefit with the addition of immunotherapy to chemotherapy. Intratumoral switching between chemosensitive and chemoresistant subtypes accompanies therapeutic resistance.
Source: Cancer CellCategories: Hem/Oncs, Latest HeadlinesTweet-
#AACR22 #LCSM Median OS in SCLC-Inflamed of >17mo (!) with chemo/IO - essentially identical to our analysis of SCLC-Inflamed in IMPower133 from Gay et al in @Cancer_Cell https://t.co/1LSXOKLOQP @MDAndersonNews https://t.co/Ymv9pRRZZG
-
-
Mashup Score: 1
Gay et al. provide a classification for four subtypes of small cell lung cancer, each with unique molecular features and therapeutic vulnerabilities. An inflamed, mesenchymal subtype predicts benefit with the addition of immunotherapy to chemotherapy. Intratumoral switching between chemosensitive and chemoresistant subtypes accompanies therapeutic resistance.
Source: Cancer CellCategories: Hem/Oncs, Latest HeadlinesTweet-
Ok, #TTLC22 @IASLC, what #SCLC needs now is a good acronym for the SCLC molecular subtypes. I’ll go first…SPAIN? (“S”CLC - “P”OU2F3 -“A”SCL1 - “I”NFLAMED - “N”EUROD1). It’s like #Wordle for #LCSM. (Note there is no “Y” as Yap1 is retired) https://t.co/1LSXOKLOQP https://t.co/0shGEPCb9D
-
-
Mashup Score: 1Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer - Cancer & Metabolism - 3 year(s) ago
Introduction The transcription factor MYC is overexpressed in 30% of small cell lung cancer (SCLC) tumors and is known to modulate the balance between two major pathways of metabolism: glycolysis and mitochondrial respiration. This duality of MYC underscores the importance of further investigation into its role in SCLC metabolism and could lead to insights into metabolic targeting approaches….
Source: Cancer & MetabolismCategories: Latest Headlines, Oncologists1Tweet-
Congratulations to Byers Lab post-doc Dr. Kasey Cargill who simultaneously published her metabolism paper on targeting glycolysis in #SCLC @MDAndersonNews and started medical school @UPMC #SCLC21 #EndCancer @TGOliver2 @teekayowo #LCSM https://t.co/AzMs9Q5fOc https://t.co/uhfoKQzlEU
-
-
Mashup Score: 0
The company reported that a lower dose of the vaccine was 90.7 percent effective in preventing symptomatic Covid-19 in a clinical trial.
Source: www.nytimes.comCategories: Latest Headlines, Oncologists1Tweet-
Good news to start Friday morning. #COVID19 @IshwariaMD https://t.co/BHNS2b6dei
-
-
Mashup Score: 14
Coronavirus disease 2019 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which enters host cells through the cell surface proteins ACE2 and TMPRSS2.
Source: Journal of Thoracic OncologyCategories: Latest Headlines, Oncologists1Tweet-
In March 2020, the Byers Lab and our collaborators @MDAndersonNews closed our labs due to #COVID19. Working remotely, we leveraged lung cancer models and patient data to study #SARSCoV2. Proud to share our paper @JTOonline #LCSM (shared 5/2020 on BioRxiv) https://t.co/3hTL7PBi5D https://t.co/ezjdCwaduQ
-
-
Mashup Score: 6Study defines small-cell lung cancer subtypes and distinct therapeutic vulnerabilities for each type - 3 year(s) ago
Researchers from The University of Texas MD Anderson Cancer Center have developed the first comprehensive framework to classify small-cell lung cancer (SCLC) into four unique subtypes, based on gene expression, and have identified potential therapeutic targets for each type.
Source: MD Anderson Cancer CenterCategories: Latest Headlines, Oncologists1Tweet-
Congratulations to Dr. CARL GAY @MDAndersonNews who received a $1.5M CPRIT Early Clinical Investigator Award to develop cutting-edge personalized approaches for patients with Small Cell Lung Cancer. #LCSM #SCLC #EndCancer https://t.co/US2hbQ2BUQ https://t.co/VWu3IhZEeD https://t.co/Rnxx60ew4Q
-
Thank you @TAMESTX for sharing our research story @MDAndersonNews #LCSM #SCLC #EndCancer https://t.co/tFEc07KSNN